Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pages G, Vilgrain I. Polena H, et al. Among authors: vilgrain i. Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563634 Free PMC article.
BIOBRAD Study: The Search for Biomarkers of Bradykinin-Mediated Angio-Oedema Attacks.
Deroux A, Dumestre-Perard C, Khalil-Mgharbel A, Maignan M, Boccon-Gibod I, Fevre MC, Vilgrain I, Bouillet L. Deroux A, et al. Among authors: vilgrain i. Int Arch Allergy Immunol. 2016;170(2):108-114. doi: 10.1159/000446959. Epub 2016 Jul 30. Int Arch Allergy Immunol. 2016. Retraction in: Int Arch Allergy Immunol. 2019;180(3):233. doi: 10.1159/000502709. PMID: 27475458 Free article. Retracted.
Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab.
Banse C, Polena H, Stidder B, Khalil-Mgharbel A, Houivet E, Lequerré T, Fardellone P, Le-Loët X, Philippe P, Marcelli C, Vittecoq O, Vilgrain I. Banse C, et al. Among authors: vilgrain i. Joint Bone Spine. 2017 Dec;84(6):685-691. doi: 10.1016/j.jbspin.2016.10.012. Epub 2016 Nov 25. Joint Bone Spine. 2017. PMID: 28011155
Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus.
Sidibé A, Polena H, Razanajatovo J, Mannic T, Chaumontel N, Bama S, Maréchal I, Huber P, Gulino-Debrac D, Bouillet L, Vilgrain I. Sidibé A, et al. Among authors: vilgrain i. Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H448-54. doi: 10.1152/ajpheart.00773.2013. Epub 2014 May 23. Am J Physiol Heart Circ Physiol. 2014. PMID: 24858855 Free PMC article.
VE-cadherin Y685F knock-in mouse is sensitive to vascular permeability in recurrent angiogenic organs.
Sidibé A, Polena H, Pernet-Gallay K, Razanajatovo J, Mannic T, Chaumontel N, Bama S, Maréchal I, Huber P, Gulino-Debrac D, Bouillet L, Vilgrain I. Sidibé A, et al. Among authors: vilgrain i. Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H455-63. doi: 10.1152/ajpheart.00774.2013. Epub 2014 May 23. Am J Physiol Heart Circ Physiol. 2014. PMID: 24858856 Free article.
56 results